Key Takeaway: A single infusion of Lu AG09222 significantly reduced migraine days over a 4-week period, suggesting it could be a promising new treatment. However, longer studies are needed to confirm its effectiveness.
Future Research: Investigate the mechanisms behind PACAP-induced migraine and how Lu AG09222 blocks this process.
PACAP is another key molecule implicated in migraine and can trigger migraine attacks. Lu AG09222, an antibody that blocks PACAP, has shown promise in reducing migraine days in a phase 2a trial.
| Potential COI | Organisation |
| Consultant/speaker/boards | AbbVie, Amgen, Astra Zeneca, Eli Lilly, Escient, GlaxoSmithKline, Lundbeck, Novartis and Teva. |
| Grant support for research (institutional) | Lundbeck Foundation, Novo Nordisk Foundation, Lundbeck and Novartis |
| Editorial Board | Associate editor of Brain Associate editor of the Journal of Headache and Pain Editorial Board – European Journal of Neurology |
| Other | None |
Citation: A Monoclonal Antibody to PACAP for Migraine Prevention
A Monoclonal Antibody to PACAP for Migraine Prevention Messoud Ashina, M.D., Ravinder Phul, Ph.D., Melanie Khodaie, Ph.D., Elin Löf, Ph.D., and Ioana Florea, M.D.
Published September 4, 2024
N Engl J Med 2024;391:800-809
DOI: 10.1056/NEJMoa2314577 VOL. 391 NO 9
The information on PainRelief.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on September 4, 2024 by PainRelief.com